Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Macrogenics Inc’s stock clocked out at $1.37, up 0.74% from its previous closing price of $1.36. In other words, the price has increased by $0.74 from its previous closing price. On the day, 0.53 million shares were traded. MGNX stock price reached its highest trading level at $1.37 during the session, while it also had its lowest trading level at $1.295.
Ratios:
To gain a deeper understanding of MGNX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.02 and its Current Ratio is at 5.25. In the meantime, Its Debt-to-Equity ratio is 2.31 whereas as Long-Term Debt/Eq ratio is at 2.20.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 19 ’25 when HEIDEN WILLIAM K bought 50,500 shares for $1.52 per share. The transaction valued at 76,760 led to the insider holds 61,500 shares of the business.
HEIDEN WILLIAM K bought 49,500 shares of MGNX for $73,755 on Aug 20 ’25. The Director now owns 111,000 shares after completing the transaction at $1.49 per share. On Feb 15 ’25, another insider, Smith Beth Ann, who serves as the VP, Controller & Treasurer of the company, sold 423 shares for $2.56 each. As a result, the insider received 1,083 and left with 9,532 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MGNX now has a Market Capitalization of 86591816 and an Enterprise Value of 17612814. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.52 while its Price-to-Book (P/B) ratio in mrq is 1.86. Its current Enterprise Value per Revenue stands at 0.106 whereas that against EBITDA is -0.25.
Stock Price History:
The Beta on a monthly basis for MGNX is 1.55, which has changed by -0.6879271 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, MGNX has reached a high of $4.87, while it has fallen to a 52-week low of $0.99. The 50-Day Moving Average of the stock is -19.47%, while the 200-Day Moving Average is calculated to be -22.34%.
Shares Statistics:
It appears that MGNX traded 771.11K shares on average per day over the past three months and 747230 shares per day over the past ten days. A total of 63.21M shares are outstanding, with a floating share count of 58.06M. Insiders hold about 8.14% of the company’s shares, while institutions hold 72.52% stake in the company. Shares short for MGNX as of 1760486400 were 3557143 with a Short Ratio of 4.61, compared to 1757894400 on 3730266. Therefore, it implies a Short% of Shares Outstanding of 3557143 and a Short% of Float of 6.92.
Earnings Estimates
. The current rating of Macrogenics Inc (MGNX) is the result of assessments by 1.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.15 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$1.71 and -$1.71 for the fiscal current year, implying an average EPS of -$1.71. EPS for the following year is -$2.78, with 1.0 analysts recommending between -$2.78 and -$2.78.
Revenue Estimates
In. The current quarter, 5 analysts expect revenue to total $28.72M. It ranges from a high estimate of $48.18M to a low estimate of $15M. As of. The current estimate, Macrogenics Inc’s year-ago sales were $110.71MFor the next quarter, 5 analysts are estimating revenue of $33.89M. There is a high estimate of $61.7M for the next quarter, whereas the lowest estimate is $9.6M.
A total of 4 analysts have provided revenue estimates for MGNX’s current fiscal year. The highest revenue estimate was $128.41M, while the lowest revenue estimate was $60M, resulting in an average revenue estimate of $88.53M. In the same quarter a year ago, actual revenue was $149.96MBased on 5 analysts’ estimates, the company’s revenue will be $102.02M in the next fiscal year. The high estimate is $214.39M and the low estimate is $11M.
